{"id":"climara","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Application site reaction","drugRate":"40.6%","severity":"common","organSystem":""},{"effect":"Breast pain","drugRate":"18.9%","severity":"common","organSystem":""},{"effect":"Upper respiratory infection","drugRate":"13.2%","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"6.1%","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"5.7%","severity":"common","organSystem":""},{"effect":"Pain","drugRate":"5.2%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"5.2%","severity":"common","organSystem":""},{"effect":"Flu syndrome","drugRate":"4.7%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"4.2%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"4.2%","severity":"common","organSystem":""},{"effect":"Bronchitis","drugRate":"4.2%","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"3.8%","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"3.8%","severity":"common","organSystem":""},{"effect":"Sinusitis","drugRate":"3.8%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"3.3%","severity":"common","organSystem":""},{"effect":"Accidental injury","drugRate":"3.3%","severity":"common","organSystem":""},{"effect":"Infection","drugRate":"3.3%","severity":"common","organSystem":""},{"effect":"Urinary tract infection","drugRate":"3.3%","severity":"common","organSystem":""},{"effect":"Weight gain","drugRate":"2.8%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"2.4%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Anaphylactic reaction","drugRate":"","severity":"serious"},{"effect":"Cardiovascular disorders","drugRate":"","severity":"serious"},{"effect":"Malignant neoplasms","drugRate":"","severity":"serious"},{"effect":"Alopecia","drugRate":"","severity":"serious"},{"effect":"Night sweats","drugRate":"","severity":"serious"},{"effect":"Pruritus","drugRate":"","severity":"serious"},{"effect":"Dizziness","drugRate":"","severity":"serious"},{"effect":"Insomnia","drugRate":"","severity":"serious"},{"effect":"Changes in bleeding patterns","drugRate":"","severity":"serious"},{"effect":"Abdominal distension","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL135","moleculeType":"Small molecule","molecularWeight":"272.39"},"aliases":["Estradiol transdermal patch"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$18.2350/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$6,656","description":"CLIMARA 0.1 MG/DAY PATCH","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[],"_dailymed":{"setId":"184d3092-7fc6-4375-816b-1ab06bb99cfd","title":"CLIMARA PRO (ESTRADIOL AND LEVONORGESTREL) PATCH [BAYER HEALTHCARE PHARMACEUTICALS INC.]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T02:31:06.264Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07420218","phase":"PHASE4","title":"Menopausal Hormones and Sympathetic Activation","status":"NOT_YET_RECRUITING","sponsor":"University of Delaware","startDate":"2026-09-01","conditions":"Perimenopausal Women","enrollment":80},{"nctId":"NCT06635447","phase":"PHASE3","title":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-26","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06533865","phase":"PHASE3","title":"Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-19","conditions":"FHA (Functional Hypothalamic Amenorrhea)","enrollment":114},{"nctId":"NCT06726148","phase":"PHASE1, PHASE2","title":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-03","conditions":"Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors","enrollment":280},{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":"Breast Cancer","enrollment":193},{"nctId":"NCT07498478","phase":"PHASE2","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","status":"RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-03-17","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT05601440","phase":"PHASE2","title":"Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2023-06-13","conditions":"Breast Cancer","enrollment":484},{"nctId":"NCT07496294","phase":"NA","title":"Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2026-04","conditions":"Menopausal Women, Menopausal Symptom Relief, Hormone Therapy","enrollment":200},{"nctId":"NCT06998407","phase":"PHASE1, PHASE2","title":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-08-20","conditions":"HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":380},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":"Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":392},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT06851754","phase":"PHASE3","title":"Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2025-07-17","conditions":"Premature Ovarian Insufficiency","enrollment":185},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT07109726","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","status":"RECRUITING","sponsor":"Terremoto Biosciences Inc.","startDate":"2025-09-23","conditions":"Breast Cancer, Endometrial Cancer, Ovarian Cancer","enrollment":205},{"nctId":"NCT07347600","phase":"","title":"A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-01-21","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT06239376","phase":"NA","title":"Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients","status":"RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2024-02-19","conditions":"Adenomyosis, IVF, Frozen Embryo Transfer","enrollment":222},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT04576455","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-27","conditions":"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","enrollment":303},{"nctId":"NCT03844412","phase":"PHASE2","title":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-11-04","conditions":"Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome","enrollment":209},{"nctId":"NCT06318403","phase":"PHASE2","title":"Estradiol Supplementation and Rotator Cuff Repair","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2028-03","conditions":"Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Syndrome","enrollment":58},{"nctId":"NCT07269327","phase":"PHASE1","title":"An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2025-11-24","conditions":"Fertility","enrollment":24},{"nctId":"NCT00099437","phase":"PHASE3","title":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2005-02-13","conditions":"Breast Cancer","enrollment":736},{"nctId":"NCT07226349","phase":"PHASE1","title":"A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-12-11","conditions":"Advanced Solid Tumor","enrollment":105},{"nctId":"NCT05654623","phase":"PHASE3","title":"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-03","conditions":"Advanced Breast Cancer","enrollment":624},{"nctId":"NCT06120283","phase":"PHASE1","title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2023-12-01","conditions":"Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT07480681","phase":"PHASE1","title":"Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-03","conditions":"Advanced/Metastatic Solid Tumors","enrollment":138},{"nctId":"NCT07358468","phase":"","title":"Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study","status":"RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2026-02-22","conditions":"Infertility, Endometrial Peristalsis, Uterine Contraction","enrollment":356},{"nctId":"NCT07038369","phase":"PHASE1","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atavistik Bio, Inc","startDate":"2025-07-29","conditions":"Advanced Solid Tumors, Breast Cancer, Breast Carcinoma","enrollment":134},{"nctId":"NCT06993844","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ensem Therapeutics","startDate":"2025-06-10","conditions":"Advanced Solid Tumors, Advanced Breast Cancer","enrollment":233},{"nctId":"NCT04191499","phase":"PHASE2, PHASE3","title":"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-01-29","conditions":"Breast Cancer","enrollment":325},{"nctId":"NCT06997029","phase":"PHASE1","title":"A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-08-01","conditions":"Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer","enrollment":234},{"nctId":"NCT03643510","phase":"PHASE2","title":"Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-21","conditions":"Adenocarcinoma of Endometrium","enrollment":28},{"nctId":"NCT05230810","phase":"PHASE1, PHASE2","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Criterium, Inc.","startDate":"2022-08-25","conditions":"HER2-positive Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT07235774","phase":"PHASE1","title":"A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2025-11-05","conditions":"Healthy Adult Female Participants","enrollment":28},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07368998","phase":"PHASE2","title":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-02-18","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT07043322","phase":"PHASE2","title":"Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-06-30","conditions":"Gynecologic Disease","enrollment":150},{"nctId":"NCT06016738","phase":"PHASE3","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2023-11-16","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":510},{"nctId":"NCT06736704","phase":"PHASE1, PHASE2","title":"SNV4818 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pikavation Therapeutics, Inc.","startDate":"2025-02-20","conditions":"Advanced Solid Tumors","enrollment":320},{"nctId":"NCT07287917","phase":"PHASE1, PHASE2","title":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Aminex Therapeutics, Inc.","startDate":"2026-01-26","conditions":"Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer","enrollment":92},{"nctId":"NCT07466498","phase":"PHASE2","title":"Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-08-01","conditions":"Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":60},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT04862663","phase":"PHASE3","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":895},{"nctId":"NCT06513104","phase":"PHASE1","title":"A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-07-18","conditions":"Diabetes Mellitus, Type 2","enrollment":47},{"nctId":"NCT05524584","phase":"PHASE2","title":"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2022-08-31","conditions":"Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer","enrollment":20},{"nctId":"NCT03006172","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2016-12-13","conditions":"Breast Cancer, Solid Tumor","enrollment":200},{"nctId":"NCT06506955","phase":"PHASE2, PHASE3","title":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","status":"ENROLLING_BY_INVITATION","sponsor":"Taiho Oncology, Inc.","startDate":"2024-10-01","conditions":"Advanced/Metastatic Cancer","enrollment":15},{"nctId":"NCT04572295","phase":"PHASE1","title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-09","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT05457972","phase":"PHASE4","title":"Postpartum Vaginal Estrogen for Breastfeeding Patients","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2025-02-22","conditions":"Breastfeeding, Postpartum Sexual Dysfunction, Vaginal Atrophy","enrollment":100},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer","enrollment":1050},{"nctId":"NCT07405801","phase":"PHASE2","title":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT03941730","phase":"PHASE2","title":"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-08-28","conditions":"Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":8},{"nctId":"NCT04451746","phase":"NA","title":"The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases","status":"COMPLETED","sponsor":"Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia","startDate":"2020-06-24","conditions":"Chronic Venous Diseases","enrollment":116},{"nctId":"NCT03531645","phase":"PHASE2","title":"Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-13","conditions":"Malignant Neoplasms of Female Genital Organs","enrollment":18},{"nctId":"NCT05551949","phase":"PHASE4","title":"Preventing Recurrent UTI With Vaginal Estrogen","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-01-01","conditions":"Recurrent Urinary Tract Infection, Urinary Tract Infections, Cystitis Recurrent","enrollment":27},{"nctId":"NCT06257264","phase":"PHASE1","title":"A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-03-11","conditions":"Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer","enrollment":258},{"nctId":"NCT07013643","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":"Healthy Participants","enrollment":75},{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT05554354","phase":"PHASE2","title":"Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma","enrollment":1},{"nctId":"NCT07446400","phase":"PHASE1","title":"A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-03-20","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT05154487","phase":"PHASE2","title":"A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GOG Foundation","startDate":"2024-09-11","conditions":"Endometroid Endometrial Cancer","enrollment":51},{"nctId":"NCT06982521","phase":"PHASE3","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Relay Therapeutics, Inc.","startDate":"2025-08-26","conditions":"PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor","enrollment":540},{"nctId":"NCT01560416","phase":"PHASE2","title":"Fulvestrant With or Without Ganetespib in HR+ Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-06","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT05768139","phase":"PHASE1, PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":"Breast Cancer, Solid Tumors, Adult","enrollment":720},{"nctId":"NCT07254429","phase":"PHASE2","title":"COMPASS - COpenhagen MenoPAuSe Study","status":"RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2025-10-02","conditions":"Menopausal Osteoporosis, Bone Markers","enrollment":192},{"nctId":"NCT07389733","phase":"PHASE1, PHASE2","title":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-02","conditions":"Advanced Unresectable or Metastatic Breast Cancer of Adults","enrollment":180},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT02860000","phase":"PHASE2","title":"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-07-06","conditions":"Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma","enrollment":96},{"nctId":"NCT01602380","phase":"PHASE3","title":"A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-10-17","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":462},{"nctId":"NCT07032506","phase":"NA","title":"Intrauterine Stent Placement Following Hysteroscopic Septum Resection","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-03","conditions":"Intrauterine Adhesion","enrollment":320},{"nctId":"NCT01597388","phase":"PHASE1","title":"AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05-08","conditions":"Advanced Metastatic Breast Cancer","enrollment":99},{"nctId":"NCT02778685","phase":"PHASE2","title":"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2016-09-30","conditions":"Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7","enrollment":47},{"nctId":"NCT07426822","phase":"PHASE2","title":"Rash & Diarrhea Prophylaxis With Capivasertib","status":"NOT_YET_RECRUITING","sponsor":"Maryam Lustberg","startDate":"2026-04","conditions":"Metastatic HR+/HER2- Breast Cancer","enrollment":108},{"nctId":"NCT03179904","phase":"PHASE2","title":"TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-08-03","conditions":"Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8","enrollment":17},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT07408089","phase":"PHASE1","title":"Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Boundless Bio, Inc.","startDate":"2026-02-25","conditions":"Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":96},{"nctId":"NCT03905941","phase":"EARLY_PHASE1","title":"Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2021-08-23","conditions":"Polycystic Ovary Syndrome","enrollment":""},{"nctId":"NCT06307184","phase":"","title":"Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer","status":"RECRUITING","sponsor":"Instituto Valenciano de Infertilidade de Lisboa","startDate":"2024-02-23","conditions":"Frozen Embryo Transfer","enrollment":530},{"nctId":"NCT06494150","phase":"PHASE2","title":"Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2024-12-26","conditions":"Low Grade Ovarian Serous Adenocarcinoma","enrollment":37},{"nctId":"NCT07288359","phase":"PHASE1, PHASE2","title":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-29","conditions":"Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer","enrollment":205},{"nctId":"NCT05022342","phase":"","title":"Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-27","conditions":"Breast Cancer","enrollment":595},{"nctId":"NCT07229209","phase":"NA","title":"Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding","status":"COMPLETED","sponsor":"Benha University","startDate":"2025-02-05","conditions":"Abnormal Uterine Bleeding, Cesarean Section Complications, Uterine Scar","enrollment":166},{"nctId":"NCT05038735","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-17","conditions":"Breast Cancer","enrollment":212},{"nctId":"NCT07422506","phase":"NA","title":"A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-01-01","conditions":"Missed Abortion, Early Pregnancy Failure","enrollment":580},{"nctId":"NCT05672901","phase":"NA","title":"Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause","status":"RECRUITING","sponsor":"Stratpharma AG","startDate":"2023-04-04","conditions":"Genitourinary Syndrome of Menopause","enrollment":100},{"nctId":"NCT07419594","phase":"NA","title":"Estradiol and Intrusive Memories","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2024-08-19","conditions":"PTSD, Intrusive Memories, Intrusion Symptom","enrollment":273},{"nctId":"NCT07421895","phase":"","title":"A Prospective Multicenter Observational Real-world Study of Retained Products of Conception","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2022-06-01","conditions":"Retained Products of Conception, RPOC","enrollment":600},{"nctId":"NCT07419776","phase":"","title":"The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-06-24","conditions":"Poly Cystic Ovary Syndrome","enrollment":90},{"nctId":"NCT07288190","phase":"PHASE2","title":"Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR","status":"NOT_YET_RECRUITING","sponsor":"HIV Prevention Trials Network","startDate":"2026-05-15","conditions":"Pregnancy, HIV Infections","enrollment":300},{"nctId":"NCT06852365","phase":"PHASE2","title":"Combined Oral Contraceptive Pill and Resistance Starch","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-06-10","conditions":"Metabolic Syndrome, Polycystic Ovary Syndrome","enrollment":100},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT05317364","phase":"PHASE4","title":"Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2022-07-14","conditions":"Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence","enrollment":38},{"nctId":"NCT07100782","phase":"PHASE3","title":"Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-12-08","conditions":"Endometriosis, Pelvic Pain","enrollment":130},{"nctId":"NCT07416578","phase":"NA","title":"Clinical Study on the Effect of Umbilical Cord Mesenchymal Stem Cell Exosomes on Endometrial Repair of Intrauterine Adhesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-01-01","conditions":"Intrauterine Adhesions, Exosomes","enrollment":60},{"nctId":"NCT07414784","phase":"PHASE1","title":"A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-02-11","conditions":"Healthy Volunteer","enrollment":20},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT02947685","phase":"PHASE3","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-06-21","conditions":"HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer","enrollment":518}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":28,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Climara","genericName":"Climara","companyName":"Seattle Institute for Biomedical and Clinical Research","companyId":"seattle-institute-for-biomedical-and-clinical-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}